ASHIBIO, INC.
🇺🇸United States
A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
Phase 2
Recruiting
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Ashibio Inc
- Target Recruit Count
- 92
- Registration Number
- NCT06508021
- Locations
- 🇺🇸
University of California San Francisco (UCSF), San Francisco, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of Pennsylvania - Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath